Home Cart Sign in  
Chemical Structure| 1434635-54-7 Chemical Structure| 1434635-54-7

Structure of Firsocostat
CAS No.: 1434635-54-7

Chemical Structure| 1434635-54-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ND-630 is an allosteric inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits ACC1 and ACC2 activity (IC50s = 2.1 and 6.1 nM, respectively, for the human enzymes).

Synonyms: ND-630; GS-0976; ND630. NDI-010976

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Firsocostat

CAS No. :1434635-54-7
Formula : C28H31N3O8S
M.W : 569.63
SMILES Code : O=C(O)C(C)(C)N(C(N(C[C@@H](C1=CC=CC=C1OC)OC2CCOCC2)C3=C4C(C)=C(C5=NC=CO5)S3)=O)C4=O
Synonyms :
ND-630; GS-0976; ND630. NDI-010976
MDL No. :MFCD28963986
InChI Key :ZZWWXIBKLBMSCS-FQEVSTJZSA-N
Pubchem ID :71528744

Safety of Firsocostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Firsocostat

ferroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse RPE-choroid tissue 100 nM 1 hour Firsocostat increases fatty acid oxidation, decreases intracellular lipid levels, diminishes lipoprotein release, and increases TEER. PMC11490839
3D liver microtissues (hLiMTs) 0.5 µM and 10 µM 10 days Firsocostat significantly decreased TG levels and reduced lipid accumulation in NASH hLiMTs. PMC8611054
Candida albicans SC5314 25 µM 24 hours To evaluate the growth-inhibitory effect of Firsocostat on C. albicans SC5314, results showed Firsocostat exhibited antifungal activity PMC10777831
Candida albicans C5 25 µM 24 hours To evaluate the growth-inhibitory effect of Firsocostat on C. albicans C5, results showed Firsocostat exhibited antifungal activity PMC10777831
Human iPSC-RPE cells 1 to 1000 nM 6 hours Firsocostat increases fatty acid oxidation, remodels lipid composition, and decreases apolipoprotein export by RPE cells. PMC11490839
Huh7 cells 1% DMSO overnight To evaluate the effect of Firsocostat in combination with other PPAR agonists on fatty acid oxidation (FAO), results showed that Firsocostat significantly increased FAO. PMC9426400

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
rats dyslipidemic rat model induced by high-fat diet Oral 10 or 30 mg/kg once daily for 4 weeks To evaluate the effect of Firsocostat on liver and circulating triglycerides (TG), results showed that Firsocostat significantly reduced liver TG but increased circulating TG. PMC9426400
C57BL/6 mice Systemic candidiasis model Intravenous injection 4 mg/kg For three consecutive days To evaluate the therapeutic effect of Firsocostat alone or in combination with VOR on systemic candidiasis, results showed the combination therapy significantly reduced fungal burden in kidneys and spleens PMC10777831

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.78mL

1.76mL

0.88mL

17.56mL

3.51mL

1.76mL

References

 

Historical Records

Categories